https://theranosticatlas.com/feed-therapy.xml 2026-10-26T06:00:00Z LaRadiopharmacie.fr https://theranosticatlas.com/therapy/#nct=NCT05475210#2026-10-26-7063 2026-10-26T06:00:00Z

177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors

https://theranosticatlas.com/therapy/#nct=NCT05547061#2026-10-23-57042 2026-10-23T06:00:00Z

A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy

https://theranosticatlas.com/therapy/#nct=NCT07887971#2026-10-23-32000 2026-10-23T06:00:00Z

A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors

https://theranosticatlas.com/therapy/#2026-10-21-29375 2026-10-21T06:00:00Z

Tracking of trials starts; each update adds new trials, changes of phase or status and published results here.

https://pubmed.ncbi.nlm.nih.gov/42879732/#2026-10-15-93730 2026-10-15T06:00:00Z

First astatine-211 antibody built into transplant conditioning (45 patients): maximum dose set by liver toxicity (veno-occlusive disease), blasts cleared in 12 of 13 patients, 1-year relapse-free survival of 42%. A phase 2 is warranted.

https://pubmed.ncbi.nlm.nih.gov/42864228/#2026-10-12-85845 2026-10-12T06:00:00Z

Two cycles of ¹⁷⁷Lu-PSMA before stereotactic radiotherapy of hormone-sensitive oligorecurrence: progression-free survival of 17.6 vs 7.4 months (HR 0.38) and delayed need for hormone therapy, with 32 months of follow-up.

https://pubmed.ncbi.nlm.nih.gov/42562607/#2026-10-01-94124 2026-10-01T06:00:00Z

3,709 patients treated in 46 French centres: progression-free survival of 7.6 months (8.7 in VISION) in older, more heavily pretreated patients, with no new safety signal; use moved to earlier lines over the programme.

https://pubmed.ncbi.nlm.nih.gov/42485097/#2026-10-01-65654 2026-10-01T06:00:00Z

The fractionated schedule (two injections 15 days apart) is chosen, with a PSA decline of more than 50% in 60% of patients; the repeated-cycle schedule, too toxic, is dropped. Thrombocytopenia is frequent.

https://pubmed.ncbi.nlm.nih.gov/42490294/#2026-10-01-40654 2026-10-01T06:00:00Z

First-in-human trial of the α-emitting MIBG analogue (10 patients): no dose-limiting toxicity up to 2.1 MBq/kg, fast urinary clearance, one partial response.

https://pubmed.ncbi.nlm.nih.gov/42518206/#2026-10-01-97326 2026-10-01T06:00:00Z

Combination with an oral radiosensitiser is feasible, but haematological toxicity is marked (grade 4 neutropenia in 7 patients, grade ≥ 3 events in 77%).

https://pubmed.ncbi.nlm.nih.gov/42803639/#2026-09-28-44692 2026-09-28T06:00:00Z

Pilot study in grade 2-3 NETs (26 patients): 35% response rate, progression-free survival of 13.3 months, but serious adverse events in more than half of the patients.

https://pubmed.ncbi.nlm.nih.gov/42785949/#2026-09-24-74032 2026-09-24T06:00:00Z

The albumin binder increases uptake but prolongs circulation: the bone marrow becomes the limiting organ (febrile neutropenia), hence a low recommended activity (1.85 GBq per cycle).

https://pubmed.ncbi.nlm.nih.gov/42785946/#2026-09-24-86271 2026-09-24T06:00:00Z

PSMA ligand with very fast clearance: low kidney and marrow doses, no limiting toxicity up to 7.4 GBq, but PSA50 in only 2 of 9 patients.

https://pubmed.ncbi.nlm.nih.gov/42732593/#2026-09-13-10654 2026-09-13T06:00:00Z

A short enzalutamide "priming" around each cycle does not improve response (PSA50 of 40%, goal not met) in patients already treated with a taxane and an ARPI.

https://pubmed.ncbi.nlm.nih.gov/42223513/#2026-09-01-16613 2026-09-01T06:00:00Z

Well tolerated up to 9.25 GBq, chosen for phase 2, but only one partial response in 27 patients: the activity of FAP targeting remains to be shown.

https://pubmed.ncbi.nlm.nih.gov/42604001/#2026-08-07-62386 2026-08-07T06:00:00Z

In first-line grade 2-3 GEP-NETs, the benefit of Lutathera holds whatever the grade and primary site (HR between 0.23 and 0.34).

https://pubmed.ncbi.nlm.nih.gov/42561994/#2026-08-06-1653 2026-08-06T06:00:00Z

Added to an ARPI and androgen deprivation, Pluvicto cuts the risk of radiographic progression or death by 28% (HR 0.72) in 1,144 patients; medians not reached. More grade ≥ 3 adverse events (51% vs 43%); dry mouth is frequent but mild.

https://pubmed.ncbi.nlm.nih.gov/42507969/#2026-07-27-95860 2026-07-27T06:00:00Z

Adding radium to cabozantinib in kidney cancer with bone metastases brings no benefit: trial stopped for futility (16.7 vs 17.6 months).

https://pubmed.ncbi.nlm.nih.gov/42392118/#2026-07-02-47231 2026-07-02T06:00:00Z

Versus everolimus in progressive G1-G2 GEP-NETs, progression-free survival of 23.9 vs 14.1 months (HR 0.67), with half as many grade 3-4 adverse events (18% vs 40%).

https://pubmed.ncbi.nlm.nih.gov/42315637/#2026-06-19-49486 2026-06-19T06:00:00Z

No limiting toxicity up to 1,000 mg/m² of capecitabine (12 patients); PSA50 of 50%. A signal to confirm in a larger cohort.

https://pubmed.ncbi.nlm.nih.gov/42225102/#2026-06-01-31198 2026-06-01T06:00:00Z

French randomized (non-comparative) trial in pretreated pancreatic NETs: 80.5% progression-free at 12 months with Lutathera vs 41.9% with sunitinib, and better quality of life. Late effects are reported and should be weighed for subsequent lines.